ArticleAJNR. American journal of neuroradiology2023
Prospective Safety Study of Intrathecal Gadobutrol in Different Doses.
Article in AJNR. American journal of neuroradiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- microGLYMPH: a conceptual translational roadmap for microdialysis‑based assessment of CSF-interstitial solute exchange in acquired brain injury.Critical care (London, England) · 2026Review
- Do enlarged white matter perivascular spaces reflect brain clearance dysfunction? Insights from intrathecal contrast-enhanced MRI.Neuroradiology · 2026Article
- Review
- Alterations of Glymphatic System Before and After Shunt Surgery in Patients With Idiopathic Normal Pressure Hydrocephalus: A Longitudinal Study.European journal of neurology · 2025Article
- Neurosurgery and the glymphatic system.Acta neurochirurgica · 2024Review
- Is CAA a perivascular brain clearance disease? A discussion of the evidence to date and outlook for future studies.Cellular and molecular life sciences : CMLS · 2024Review
- Glymphatic-lymphatic coupling: assessment of the evidence from magnetic resonance imaging of humans.Cellular and molecular life sciences : CMLS · 2024Review
- Magnetic force-based cell manipulation forAPL bioengineering · 2023Review
- Mechanisms behind changes of neurodegeneration biomarkers in plasma induced by sleep deprivation.Brain communications · 2023Article
- Intravenous Contrast-Enhanced MR Myelography in CSF Leakage for the Detection of Spinal CSF Lamellae.Journal of neuroimaging : official journal of the American Society of NeuroimagingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeIn our clinical practice, we increasingly use intrathecal contrast-enhanced glymphatic MR imaging to assess CSF disturbances. However, because intrathecal MR imaging contrast agents such as gadobutrol (Gadovist; 1.0 mmol/mL) are used off-label, a thorough understanding of the safety profile is required. MATERIALS AND
methodsWe performed a prospective safety study from August 2020 to June 2022 of intrathecal gadobutrol, including consecutive patients who received either 0.50, 0.25, or 0.10 mmol. Serious and nonserious adverse events were recorded systematically at 1-3 days, 4 weeks, and >6 months after the intrathecal administration.
resultsThe study included 196 patients who received intrathecal gadobutrol, including patients assessed for idiopathic normal pressure hydrocephalus (iNPH,
conclusionsThe present study adds to the accumulating evidence that intrathecal gadobutrol in doses up to 0.50 is safe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.